For node-positive, early breast cancer patients
The Oncotype DX Breast Recurrence Score® result is predictive of chemotherapy benefit in your patients with HR+, HER2-, node-positive (1-3 positive nodes), early-stage, invasive breast cancer.1 Data from comprehensive research show that a substantial proportion of these patients may be safely spared chemotherapy1-4,9
How does the Oncotype DX test guide treatment decisions?
- Patients with Recurrence Score results 0–17 did not benefit from the addition of chemotherapy to endocrine therapy in the SWOG-8814 randomised clinical study.1 Real-world studies confirmed positive clinical outcomes in N1 patients with Recurrence Score results 0–17 on endocrine therapy alone.2,3
- Patients with Recurrence Score results 31–100 derived on average a 19% absolute benefit from the addition of chemotherapy to endocrine therapy.1
How does the Oncotype DX test reduce the risk of overtreatment?
A significant proportion of patients have tumours with low Recurrence Score results across N0, N1mi, and N+ populations4
Nodal status, despite being prognostic, does not predict the Recurrence Score result4
Overall, 610,350 tumor specimens were examined by the Genomic Health laboratory from February 2004 to August 20174
The Oncotype DX test reduces the risk of overtreatment
of node positive patients tested in real world with the Oncotype DX test have a Recurrence Score result 0-17 and may be overtreated without testing
Nodal status, despite being of prognostic value, does not predict underlying tumor biology/chemosensitivity
Clinical utility of the Oncotype DX assay
Adjuvant chemotherapy may now be guided with the Oncotype DX test to identify the majority of node-positive patients who will not benefit from the addition of chemotherapy.
The Oncotype DX Breast Recurrence Score* test should be used for:
- All patients for whom chemotherapy can potentially be spared
- All patients for whom chemotherapy can potentially be life-saving
*For early stage, HR+, HER2- patients with up to 3 nodes involved